Search

everythinglearnresearchcommunity

for

Search:↓

Stopping RU58841 may result in losing only the hair gained from it, unlike stopping Minoxidil, which can lead to losing more hair. The discussion compares the dependency effects of RU58841 and Minoxidil on hair.

The conversation discusses hair loss treatments, specifically using a Dermaroller, Minoxidil, and RU58841 for two months. The user shared progress pictures showing the results of these treatments.

Glycine supplementation may increase 5-alpha reductase activity, potentially affecting hair loss. Users discuss its impact on hair fall and its role in the body.

After six months of using topical minoxidil once daily and oral finasteride every three days, the user saw improvement in hair thickness, particularly at the crown, and some new hair growth at the hairline. They also used a 1.5mm dermaroller weekly, which they believe contributed to their progress.

A 54-year-old user shares progress after 3 years on dutasteride, following 15 years on finasteride, using 0.5 mg/day dutasteride, topical minoxidil every other day, and a peptide serum on alternate days. They experienced a significant shed during the transition but are now maintaining hair, noticing some new growth along the hairline.

The user experienced hair thickening and reduced shedding using minoxidil, finasteride, and dutasteride, with a switch from finasteride to dutasteride due to ineffectiveness. They also use a saw palmetto shampoo and take vitamin D3 supplements, while considering potential underlying causes like vitamin deficiencies and hard water buildup.

VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.

A 19-year-old discusses feelings of envy towards men with full heads of hair, sharing their experience with hair loss since age 16. They have been using oral minoxidil and topical finasteride for two years, with initial improvement but continued shedding, and are considering switching to dutasteride.

Epristeride is a selective 5 alpha reductase type 2 inhibitor that may reduce scalp DHT similarly to finasteride, with potentially fewer side effects. It is suggested that combining epristeride with finasteride or dutasteride could enhance hair loss treatment effectiveness.

Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.